Knowledge at the heart of leadership
Welcome to Liftstream - Life Sciences Executive Search and Leadership Advisory

Jeremy Levin hauls in $75m Series B for Ovid

Ovid Therapeutics Inc. (Ovid), a privately held biopharmaceutical company focused on developing therapies for rare and orphan diseases of the brain, announced today that it has completed a Series B financing totaling $75 million. Fidelity Management and Research Company led the investment syndicate, which included Cowen Private Investments, Sanofi-Genzyme BioVentures, Tekla Capital Management, Sphera Global Healthcare Fund, Jennison Associates (on behalf of certain clients), Redmile Group, and Cormorant Asset Management, as well as additional blue chip mutual funds and leading life sciences investors. Existing Ovid investors, including DoubleLine Equity Healthcare Fund, LLC, also participated in the financing.

“Looking to the future, this financing is an important next step toward our goal to build Ovid into a leading neurology company.”

“Over the last year, we have rapidly executed on our strategy with the support of our investors, patients, their families, foundations, physicians, and corporate partners,” said Dr. Jeremy Levin, Chief Executive Officer and Chairman of Ovid. “Looking to the future, this financing is an important next step toward our goal to build Ovid into a leading neurology company.”

Ovid plans to use the proceeds from the Series B financing to advance its product candidates, including OV101 for Angelman Syndrome and Fragile X Syndrome. Phase 2 clinical testing is expected to commence in both patient groups in 2016. In addition, Ovid plans to use the funds to advance several other internal compounds into clinical testing, and to further expand its pipeline.

“We are pleased to secure this syndicate of top-tier investors,” said Dr. Yaron Werber, Chief Financial Officer. “This oversubscribed financing will provide significant latitude for business and corporate development initiatives and allow us to further accelerate Ovid’s programs.”

 

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases | Tagged , , , , , , | Leave a comment




Contact Us

   Head Office
Liftstream Ltd.
111 Buckingham Palace Road,
London,
SW1W 0SR
   Tel: ​+44 (0)20 3180 5880
   info@liftstream.com

Register your CV

Apply for sector specific vacancies or request a confidential discussion



Registered in England No: 5009233
VAT: 843679292

Follow Us





Sitemap